HRTX Q3 2021 Earnings — Heron Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

HRTXHeron Therapeutics, Inc.

$153M

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$23M+16.4% YoY

Gross Profit

$12M51.1% margin

Operating Income

-$52M-222.6% margin

Net Income

-$52M-225.6% margin

EPS (Diluted)

$-0.51

QoQ Revenue Growth

+3.5%

Cash Flow

Operating Cash Flow

-$53M

Free Cash Flow

-$55M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$352M

Total Liabilities

$234M

Stockholders' Equity

$119M

Cash & Equivalents

$160M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$23M	$20M	+16.4%
Gross Profit	$12M	$13M	-7.2%
Operating Income	-$52M	-$58M	+11.4%
Net Income	-$52M	-$58M	+10.0%

Revenue Segments

C I N V A N T I

$18M78%

S U S T O L

$3M13%

Z Y N R E L E F

$2M9%